STOCKHOLM, Dec 10, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development
Read the full magazine through the link below.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.
CONTACT:
Peter Benson
Chairman of the Board of Directors
+46-706-691-100
+45-40-80-48-69
http://www.alligatorbioscience.com
benson@sunstone.eu
Cecilia Hofvander
Director IR & Communications
+46-46-286-42-80
http://www.alligatorbioscience.com
ir@alligatorbioscience.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/alligator-bioscience/r/frontier---a-magazine-about-alligator-bioscience-and-immuno-oncology,c2696727
The following files are available for download:
https://mb.cision.com/Main/12681/2696727/960645.pdf | Frontier - A Magazine about Alligator Bioscience and Immuno-oncology #2, 2018 |
http://news.cision.com/alligator-bioscience/i/frontier-nr-2-2018-eng-cover,c2544074 | Frontier nr 2 2018 ENG cover |
